Kinoxis Therapeutics Pty Ltd

Eryn Werry

Michael Kassiou

William Jorgensen

Tristan Reekie

Michael Thomas Bowen

Iain Stewart McGregor

Damien Gulliver

Timothy Katte

Iain Mcgregor

Disclosed herein are compounds according to Formula I; a pharmaceutical composition including, consisting essentially of, or consisting of: a pharmaceutically acceptable compound of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient; the use of compounds of Formula I in the preparation of a medicament; and a method including administering a pharmaceutical compositions comprising the compound of Formula I to a patient. The compounds, compositions, use, and methods are directed to the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders.

Non-peptide oxytocin receptor agonists

The present disclosure relates to compounds of Formula I being cyclic metabolites of oxytocin. These derivatives have enhanced selectivity for the oxytocin receptor.

Metabolite inspired selective oxytocin receptor agonists

Growing community of inventors

New South Wales, Australia

Eryn Werry